Second anticancer CAR T therapy receives FDA approval
Sign Up to like & getrecommendations! Published in 2017 at "Nature Reviews Drug Discovery"
DOI: 10.1038/nrd.2017.249
Abstract: The approval of axicabtagene ciloleucel was based on a 101‐patient pivotal trial, which showed third‐line use of the therapy resulted in an objective response rate of 72% and a complete remission rate of 51% in… read more here.
Keywords: anticancer car; approval; car; car therapy ... See more keywords